Literature DB >> 12852231

Lymphoma updates.

Timothy M Fan1.   

Abstract

Canine and feline lymphoma is a common hematopoietic malignancy that generally responds well to systemic chemotherapy. In dogs, several recent investigations have underscored the beneficial effects of adjunctive radiation therapy for the treatment of multicentric lymphoma. With the emergence of effective immunotherapeutic agents against non-Hodgkin's lymphoma in people, some of these specific targeted immunotherapeutics may soon be a viable option for treating lymphoid malignancies in dogs. Although the effective and durable treatment of feline lymphoma remains disappointing, the identification of environmental etiologic factors may help to shape future recommendations for disease prevention. It is only reasonable to assume that as our fundamental understanding of lymphoid malignancies grows, better diagnostic tools, predictive markers, and therapeutic options will also emerge.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12852231     DOI: 10.1016/s0195-5616(03)00005-6

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  5 in total

1.  Detection of retinoid receptors in non-neoplastic canine lymph nodes and in lymphoma.

Authors:  Carlos H de Mello Souza; Victor E O Valli; Barbara E Kitchell
Journal:  Can Vet J       Date:  2014-01       Impact factor: 1.008

2.  Choanal lymphosarcoma in a 7-year-old golden retriever: diagnosis and treatment.

Authors:  Catharine A Shankel
Journal:  Can Vet J       Date:  2005-02       Impact factor: 1.008

3.  Morphological characterization of canine retrobulbar lymphoma.

Authors:  Natthanet Sritrakoon; Kannika Siripattarapravat; Phudit Maneesaay; Chidozie J Amuzie; Aree Thayananuphat
Journal:  Open Vet J       Date:  2018-10-14

4.  Large B-cell lymphoma in a dog: A cyto-histopathological evaluation and Immunophenotyping according to WHO classification for canine lymphomas.

Authors:  Zahra Nikousefat; Mohammad Hashemnia; Moosa Javdani
Journal:  Vet Res Forum       Date:  2016-03-15       Impact factor: 1.054

5.  Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.

Authors:  Abbey R Sadowski; Heather L Gardner; Antonella Borgatti; Heather Wilson; David M Vail; Joshua Lachowicz; Christina Manley; Avenelle Turner; Mary K Klein; Angharad Waite; Alexandra Sahora; Cheryl A London
Journal:  BMC Vet Res       Date:  2018-08-24       Impact factor: 2.741

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.